Literature DB >> 773842

Subclass typing of IgG antibodies formed by grass pollen-allergic patients during immunotherapy.

M van der Giessen, W L Homan, G van Kernbeek, R C Aalberse, P H Dieges.   

Abstract

The subclasses of IgG antibodies formed by grass pollen-allergic patients during immunotherapy were investigated by using a radioallergosorbent test (RAST) and a quantitative immunofluorescence method known as the defined antigen substrate spheres (DASS) system. By the use of rabbit antisera directed against the subclasses of IgG, the specificity of which was checked in the passive hemagglutination and immunofluorescence techniques, it was shown that a relatively high proportion of the grass pollen-specific antibodies belonged to the IgG4 subclass. Apart from the high binding activity of IgG4 which increased during treatment, a moderate binding activity of the other subclasses was also found. Binding of all subclasses increased slightly in the pollen season and could be specifically blocked by perincubation with soluble grass pollen extract. The results of the IgG4 binding, determined in vitro with the DASS system, and the blocking activity of the sera, determined in vivo by skin tests are suggestive for a relation between these activities. Also in the group of patients with a low IgE-RAST score, the skin reactivity decreased as the IgG4 binding activity increased.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 773842     DOI: 10.1159/000231566

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  31 in total

1.  Serum IgG subclass antibodies to a variety of food antigens in patients with coeliac disease.

Authors:  M Hvatum; H Scott; P Brandtzaeg
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

2.  Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites.

Authors:  J Schuurman; R Van Ree; G J Perdok; H R Van Doorn; K Y Tan; R C Aalberse
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

Review 3.  IgG4 breaking the rules.

Authors:  Rob C Aalberse; Janine Schuurman
Journal:  Immunology       Date:  2002-01       Impact factor: 7.397

4.  IgG4 production against adalimumab during long term treatment of RA patients.

Authors:  Pauline A van Schouwenburg; Charlotte L Krieckaert; Michael Nurmohamed; Margreet Hart; Theo Rispens; Lucien Aarden; Diana Wouters; Gerrit Jan Wolbink
Journal:  J Clin Immunol       Date:  2012-05-24       Impact factor: 8.317

5.  Immunological studies on bee-keepers: specific IgG and subclass typing IgG against bee venom and bee venom components.

Authors:  R Urbanek; J Forster; J Ziupa; D Karitzky
Journal:  Klin Wochenschr       Date:  1980-11-17

6.  Membrane receptors for the IgG4 subclass on human basophils and mast cells.

Authors:  T Nakagawa; A L de Weck
Journal:  Clin Rev Allergy       Date:  1983-06

7.  Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders.

Authors:  E Brouwer; J W Tervaert; G Horst; M G Huitema; M van der Giessen; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

8.  Immunoglobulin G subclasses of fluorescent anti-Treponema pallidum antibodies: evidence for sequential development of specific anti-T. pallidum immunoglobulin G responses in patients with early syphilis.

Authors:  J J van der Sluis; E C van Reede; M Boer
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

9.  IgG subclass distribution of antibodies against S. aureus teichoic acid and alpha-toxin in normal and immunodeficient donors.

Authors:  L Hammarström; M Granström; V Oxelius; M A Persson; C I Smith
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

10.  [From the allergen-recognition by antibodies to new therapeutic concepts].

Authors:  Brigitte Hantusch; Erika Jensen-Jarolim
Journal:  Wien Med Wochenschr       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.